Treatment protocols and management of retained fetal membranes in cattle by rural practitioners in Belgium by Eppe, Justine et al.
Preventive Veterinary Medicine 188 (2021) 105267
Available online 20 January 2021
0167-5877/© 2021 Elsevier B.V. All rights reserved.
Treatment protocols and management of retained fetal membranes in cattle 
by rural practitioners in Belgium 
Justine Eppe a, Thomas Lowie b, Geert Opsomer b, Giles Hanley-Cook c, Maya Meesters b, 
Philippe Bossaert a,* 
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A B S T R A C T   
Retained fetal membranes (RFM) is a frequent postpartum disorder in cattle causing considerable economic 
losses, and a common indication for antibiotic (AB) administration. There is controversy with regard to the 
treatment of RFM, and scientific recommendations are often in conflict with current legislation on AB use and 
practical routines in the field. 
The aim of this study was to assess the therapeutic approaches of RFM by Belgian rural veterinarians. A digital 
survey was sent to 468 Belgian veterinarians; 149 complete questionnaires (Wallonia: 78; Flanders: 71) were 
obtained. Survey questions captured socio-demographic characteristics, case definition, therapeutic approaches 
and treatment options for RFM. Questions on treatment were duplicated for dairy and beef cattle. 
When confronted with dairy cows suffering from RFM without fever, 35.6 % of vets do not treat with AB, while 
the majority administers AB, either intrauterine (47.6 %), systemically (10.7 %) or both (6.1 %). Dairy cows with 
RFM and fever receive a systemic (33.5 %), intrauterine (2.7 %) or combined (61.8 %) AB treatment. For a beef 
cow with RFM without fever, 21.5 % of vets prefer no AB treatment, while others prefer an intrauterine (24.2 %), 
systemic (24.8 %), combined (29.5 %) AB treatment. Beef cows with RFM and fever receive AB from the large 
majority of vets, by systemic (34.9 %) or combined (56.3 %) administration. In case of a parenteral treatment, 
benzylpenicillin, amoxicillin and ampicillin are by far the most frequently used molecules; only a minority of vets 
use cephalosporins. Manual placental removal is attempted by 93.9 % of the respondents. 
These results demonstrate that there is room for improvement when considering the treatment protocols of 
RFM. Many veterinarians use AB in RFM cows not presenting symptoms of general illness, or administer in-
trauterine AB in cows with or without clinical signs of illness. Concerning the molecules of choice, practical 
routines are largely in line with national AB recommendations. Beef cows suffering from RFM are treated more 
rigorously than dairy cows, regardless of their rectal temperature.   
1. Introduction 
Retained fetal membranes (RFM) in cattle is defined as the non- 
expulsion of fetal membranes beyond 24 h after calving (Fourichon 
et al., 2000; Bourne et al., 2006; Beagley et al., 2010). Gohary and 
LeBlanc (2018) estimated the economic cost of a RFM case to be $297, 
due to production losses, treatment costs, reproductive disorders and 
increased culling risk. Indeed, cows with RFM are more likely to develop 
secondary health problems that require treatment, such as puerperal 
metritis in the short term (Dubuc et al., 2010) or displaced abomasum in 
the long term (Gröhn et al., 1995). Puerperal metritis is defined as the 
presence of an abnormal, fetid smelling vaginal discharge, an enlarged 
uterus and often systemic illness between 0 and 21 days post-partum 
(Sheldon, 2004; Sheldon et al., 2009). The production losses caused 
by RFM alone are estimated to be 753 kg of milk per lactation, with an 
additional 259 kg if puerperal metritis develops (Dubuc et al., 2011). 
Furthermore, cows with RFM have an increased risk for delayed cyclicity 
and lower pregnancy rates (Peters and Laven, 1996; Gröhn and 
Rajala-Schultz, 2000). The average annual incidence of RFM varies from 
3 to 10–12 %, but is highly variable between farms and can reach up to 
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30 % (Kimura et al., 2002; Bourne et al., 2006; Drillich et al., 2006b). 
Despite the high incidence and considerable economic impacts, there 
is currently no consensus on the treatment of RFM. Several treatment 
options for RFM exist, including manual removal, intrauterine antibiotic 
(AB) therapy, systemic AB therapy and hormone treatment (Peters and 
Laven, 1996; Beagley et al., 2010; Pyörälä et al., 2014). Recently 
developed or future treatment options include ozone treatment (Djuricic 
et al., 2012; Imhof et al., 2019) and collagenase injection in the um-
bilical arteries (Guérin et al., 2004). In a clinical trial comparing four 
therapeutic approaches in over 500 RFM cases (Drillich et al., 2006a), 
manual removal of the placenta, preventive intrauterine AB adminis-
tration, or the combination of both appeared to have only marginally 
positive effects on the risks of puerperal metritis, and no effects on 
reproductive performance, when compared to systemic AB treatment in 
selected cases of systemic illness. The same research group (Drillich 
et al., 2006b) found no advantage in the disease evolution or repro-
ductive performance of RFM cows receiving preventive systemic AB 
therapy (i.e., regardless of illness), compared to selective systemic AB 
therapy for cows. Altogether, these studies suggest AB administration, 
preferably systemically, for cows presenting systemic illness as the 
preferred therapeutic approach, without preventive intrauterine or 
systemic AB administration or manual placenta removal (Drillich et al., 
2006a; Lima et al., 2014). 
The most common germ identified in uterine swabs from puerperal 
metritis cows is Escherichia coli, alone or in combination with Gram 
positive cocci, Fusobacterium necrophorum, Clostridium spp. or Trueperella 
pyogenes (Ordell et al., 2016). Ceftiofur is the most documented AB 
molecule in clinical trials on RFM and puerperal metritis treatments 
(Drillich et al., 2003, 2006a, 2006b; Haimerl et al., 2017). However, in 
the current societal context, the routine use of a third generation 
cephalosporin can no longer be justified: according to the Belgian Centre 
of Expertise on AntiMicrobial Consumption and Resistance in Animals 
(AMCRA, 2020a, 2020b), ceftiofur is regarded as a molecule of critical 
importance, for which the use should be restricted unless an antibiogram 
indicates its need. Penicillin, ampicillin and oxytetracyclin are suggested 
in the literature as alternatives for ceftiofur for the systemic treatment of 
puerperal metritis (Lima et al., 2014; Pyörälä et al., 2014). 
Finally, it should be noted that the Belgian Blue (BB) breed, which 
routinely undergoes elective caesarian section (CS), is the predominant 
beef breed in Belgium (Djebala et al., 2019). The risk for complications 
(e.g. RFM) and associated economic losses might be very different in an 
incised uterus, and therefore veterinarians’ treatment routines might 
differ from their approach in dairy cows. However, to the best of our 
knowledge, no information is currently available on the treatment habits 
for BB cows suffering from RFM. 
The aim of our study was to take stock of the treatment habits and 
decision-making criteria of Belgian rural veterinarians when treating 
dairy and beef cows suffering from RFM, and to investigate whether 
these habits are coherent with current scientific literature and national 
recommendations on AB use. 
2. Materials and methods 
The present study is based on a survey, which resulted from collab-
oration between Ghent University and the University of Liège. The 
questionnaire containing 54 questions was offered on an online platform 
(LimeSurvey) between October and December 2019, and shared through 
e-mail listings of referring veterinarians of the University Veterinary 
Clinics in Ruminants in Ghent (194 rural veterinarians contacted by e- 
mail) and Liège (274 rural veterinarians contacted by e-mail). In addi-
tion, a call for the Flemish survey was shared through the monthly 
newsletters of DGZ (Dierengezondheidszorg Vlaanderen) addressed to 
cattle veterinarians. 
The questionnaire was divided into six main sections: 1) de-
mographic information, 2) case definition of RFM, 3) therapeutic 
approach, 4) treatment options, 5) risk factors for RFM and 6) 
preventive measures against RFM. In the present manuscript, only the 
results of the demographic variables, case definition, therapeutic 
approach and treatment options will be discussed; the corresponding 
questions are displayed in Appendix 1. Several question types were used, 
and veterinarians had the opportunity to give additional clarification to 
certain questions. The demographic variables section contained 
multiple-choice questions with regard to sex (male or female), university 
of graduation (Liège, Ghent or other) and years of practical experience 
(under 10, 11–20, 21–30, above 30). Region (Flanders or Wallonia) in 
which the respondent was practicing was included as an additional de-
mographic variable. In the case definition section, a multiple-choice 
question was asked about the duration of non-expulsion with regard 
to the definition of RFM (> 6 h, > 12 h, > 24 h, > 36 h or > 48 h). The 
therapeutic approach section contained multiple-choice questions about 
diagnostic practices (taking temperature and performing a vaginal 
exploration: always, sometimes or never) and decisive elements for 
therapeutic decisions (fever, anorexia, abdominal straining, milk drop, 
dehydration). The treatment option section contained a multiple-choice 
question on manual removal (no, manual traction only, manual traction 
and detachment). Additionally, a multiple-choice question was asked on 
the route of AB administration (none, intrauterine, systemic, and com-
bined) when consulting a RFM dairy cow with or without fever. Ques-
tions about AB treatment were duplicated for beef cattle, for whom an 
additional administration option was included (intraperitoneal or other 
routes). Furthermore, 5-point Likert scale questions were asked about 
the administration (1: never; 2: rarely; 3: sometimes; 4: often; 5: always) 
of different molecules for intrauterine use (tetracyclins, cephapirine, 
water with antiseptics, povidone-iodine solution) and systemic use 
(tetracyclins, β-lactams: benzylpenicillin, amoxicillin and ampicillin, 
trimethoprim-sulfadiazine, macrolides, aminoglycosides alone or in 
combination, cephalosporins). In the Flemish questionnaire, a further 
distinction was made between 1st generation and 3rd generation 
cephalosporins. Finally, 5-point Likert scale questions were asked about 
the preference (1: never; 2: rarely; 3: sometimes; 4: often; 5: always) for 
hormonal treatment (synthetic prostaglandins, natural prostaglandins, 
oxytocin, oxytocin long acting, GnRH). 
Data management and statistical analyses were conducted in Stata 
version 14.2 (StataCorp, 2015). Descriptive statistics [median (inter-
quartile range) for ordinal variables and n (%) for categorical variables] 
were carried out. Furthermore, as a sensitivety analysis, the influence of 
demographic variables (sex, years of experience, university of gradua-
tion, region) on the outcomes were analyzed. For ordinal dependent 
variables (Likert scales, score of preference), bivariate ordered logistic 
regression models were fitted, including the socio-demographic vari-
ables as independent variables. For binary outcomes (yes or no, dummy 
variables for multiple choice questions), bivariate logistic regression 
models were fitted, including the same socio-demographic variables as 
covariates/predictors. 
Due to the lack of a regional effect on the responses (<10 % change- 
in-estimate (CIE) criterion for odds ratios (ORs) and all P > 0.05), 
Flemish and Walloon survey data were pooled in order to increase sta-
tistical power. 
A two-sided significance level of P < 0.05 was applied for all 
analyses. 
3. Results 
3.1. Demographic variables 
A total of 149 completely filled in questionnaires were obtained, of 
which 78 by Walloon and 71 by Flemish veterinarians. Walloon re-
spondents were all reached by e-mail, while Flemish respondents were 
reached by e-mail (n = 59) or the DGZ newsletter (n = 12). 
The university of graduation of the respondents was Ghent (48.3 %), 
Liège (50.4 %) and Utrecht (1.3 %). The majority of respondents (83.9 
%) were male. The years of experience of the responding vets have been 
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categorized into: <10 years (30.9 %), 11–20 years (17.5 %), 21–30 years 
(22.1 %) and > 30 years (29.5 %). 
The ORs of bivariate (ordered) logistic regression models (including 
sex, years of experience, university of graduation) were lower than our 
10 % CIE criterion and non-significant (all P > 0.05). Therefore, no 
descriptive subgroup analyses of study outcomes were conducted for 
available socio-demographic variables. 
3.2. Case definition 
The large majority of veterinarians (71.8 %) define a case of RFM as a 
non-expulsion of the placenta beyond 24 h after calving, compared to 
other categories (>6 h: 2.1 %; >12 h: 22.2 %; > 36 h: 2.6 %; >48 h: 1.3 
%). 
3.3. Therapeutic approach 
Considering the diagnosis, 64.5 % of the surveyed practitioners al-
ways take the temperature of a cow with RFM, while 8.7 % never do and 
26.8 % sometimes do. In the comments sections, its decisive value for 
the treatment choice was mentioned as the main reason for taking the 
temperature. A vaginal exploration is systematically done by the ma-
jority of respondents (73.8 %), while 7.4 % never do so and 18.8 % 
sometimes do. The main motivation to perform a vaginal examination is 
to exclude vaginal lesions, to confirm the diagnosis of RFM, to check if 
the placenta is loose enough and to attempt manual removal of the 
placenta. 
According to the respondents, a recently calved cow is considered to 
have fever when her temperature is above 39 ◦C (30.9 %), 39.5 ◦C (59 
%) or 40 ◦C (10.1 %). The presence or absence of fever influences the 
treatment of RFM for 84.6 % of the respondents. Many veterinarians 
marked other criteria influencing the treatment decision, such as, in 
order of importance, anorexia, abdominal straining and milk drop. 
3.4. Treatment options 
A large majority (93.9 %) of practitioners attempt manual removal of 
the placenta; 52.3 % only apply gentle traction and 41.6 % try to 
physically detach the placenta from the caruncular crypts. 
When confronted with dairy cows with RFM without fever (Fig. 1), 
35.6 % of vets do not treat with AB; the other vets administer AB, either 
locally, i.e. intrauterine (47.6 %), systemically (10.7 %) or both (6.1 %). 
When consulting a dairy cow with RFM and fever (Fig. 1), the large 
majority of vets treat with AB, either by combined (61.8 %), systemic 
(33.5 %) or local administration (2.7 %), while 2 % do not administer 
AB. When seeing a beef cow with RFM without fever (Fig. 2), 21.5 % of 
vets prefer no AB treatment; the other respondents apply AB, either 
locally (24.2 %), systemically (24.2 %), combined (29.5 %) or via 
another administration route (intraperitoneally; 0.6 %). Beef cows with 
RFM and fever (Fig. 2) receive AB from the large majority of vets, either 
systematically (34.9 %), intrauterine (0.7 %), or combined (56.3 %), or 
via another AB administration route (7.4 %; intraperitoneally), while 
0.7 % of respondents do not administer any AB. 
Respondents were asked to rank a number of molecules in order of 
preference (1: never used, 2: rarely used, 3: sometimes used, 4: often 
used, 5: always used), for local or systemic use. Considering intrauterine 
treatment, the ranking in declining order of preference was: tetracy-
clines, water with antiseptics, povidone-iodine solution and cefapirin. 
The AB molecules used for systemic treatment that received the highest 
preference score (4 or 5), were: β-lactams (benzylpenicillin, amoxicillin 
and ampicillin) (dairy: 75.2 %; beef: 79.8 %), tetracyclins (dairy: 29.5 
%; beef: 35.6 %), trimethoprim-sulfadiazine (dairy: 20.2 %; beef: 12.8 
%), aminoglycosides alone or in combination (dairy: 12.7 %; beef: 19.5 
%), cephalosporins (dairy: 20.6 % for all cephalosporins, 23.9 % for 1st 
generation, 4.2 % for 3rd generation; beef: 9% for all cephalosporins, 4.2 
% for 1st generation, 5.6 % for 3rd generation) and macrolides (dairy: 
5.4 %; beef: 6%). Only the Flemish questionnaire made a further 
distinction between 1st generation and 3rd generation cephalosporins. 
Results of these questions are presented in Tables 1 and 2. 
The same ranking was proposed for the use of hormones in the 
treatment of RFM, more specifically synthetic and natural prostaglan-
dins, GnRH, oxytocin and long acting oxytocin. A large majority of re-
spondents rarely or never use hormones for RFM treatment: the 
percentage of veterinarians attributing a score of 1 and 2 was 70.3 % for 
synthetic prostaglandins, 63.5 % for natural prostaglandins, 93.9 % for 
GnRH, 55.4 % for oxytocin, and 76.2 % for long acting oxytocin. 
4. Discussion 
The results of our study demonstrate that AB are largely used for the 
treatment of RFM, in cows with (dairy: 98 %; beef: 99.3 %) and without 
fever (dairy: 64.4 %; beef: 78.5 %). Since the use of AB stimulates the 
development of AB resistance in bacteria (Chantziaras et al., 2013), 
veterinarians are encouraged to rationalize their AB treatments. This 
implies knowledge of pertinent clinical studies, defining in which con-
ditions AB use can be avoided, and how AB can be applied correctly 
when necessary. Good veterinary practice also implies the adherence to 
national legislation. The AMCRA expertise center aims to reduce Belgian 
veterinary AB use, especially for molecules of critical importance, and 
provides practical recommendations (AMCRA 2020a, 2020b). However, 
scientific literature, AMCRA recommendations, treatment routines by 
Fig. 1. Antibiotic (AB) treatment choices for retained fetal membranes in dairy 
cattle depending on the presence or absence of fever. 
Fig. 2. Antibiotic (AB) treatment choices for retained fetal membranes in beef 
cattle depending on the presence or absence of fever. 
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veterinarians and expectations by farmers are not always in line. In 
particular, concerning the treatment of RFM and puerperal metritis, the 
scientific literature often describes a systemic treatment with ceftiofur 
(Drillich et al., 2003, 2006a, 2006b; Haimerl et al., 2017), while the use 
of this molecule is strongly discouraged from a legislative point of view. 
The current survey is useful to identify treatment habits of veterinarians, 
to assess whether these habits are in line with the scientific literature 
and legislation, and to identify areas for improvement. We are not the 
first to take an interest in this issue, since a similar survey was recently 
published in Switzerland (Hehenberger et al., 2015). However, since the 
type of breed, the available products and the national legislation differ 
between countries, these data cannot be extrapolated to the Belgian 
context. 
All regions and experience categories are well represented in our 
survey. Most of the responding practitioners are male. Demographic 
elements like sex, university of graduation, years of practical experience 
and region did not seem to influence the responses. Our study might 
have bias, because the cross-sectional nature of our data infers that our 
analysis might be hampered by omitted confounding and missing data 
(only complete questionnaires were analyzed). Another bias could be 
found in the AB questions: cephalosporins were subdivided in first and 
third generation in the Flemish, but not the Walloon questionnaire. 
There seems to be a consensus about the case definition of RFM: most 
practitioners apply the currently established definition of RFM as the 
non-expulsion of fetal membranes beyond 24 h after calving (Fourichon 
et al., 2000; Bourne et al., 2006; Beagley et al., 2010). The majority of 
respondents always take the temperature and perform a vaginal exam-
ination of a RFM patient. Fever, mostly defined as a rectal temperature 
above 39.5 ◦C, was generally recognized as a criterion for choice for 
treatment, as suggested in literature (Drillich et al., 2001; Lima et al., 
2014; Pohl et al., 2016). Vaginal examination can be necessary to 
confirm the diagnosis, for instance when the fetal membranes are not 
externalized (Gilbert, 2018), but another important motive for vaginal 
exploration seems to be the manual removal of the placenta, which is 
done by a large majority of respondents. This practice of manual 
removal of the placenta does not seem to be a uniquely Belgian practice, 
since another recent study came to the same conclusion (Hehenberger 
et al., 2015). Manual placenta removal has proven to be ineffective to 
avoid systemic illness or improve reproductive performance (Drillich 
et al., 2006). The detachment of the cotyledons from the caruncular 
crypts should be discouraged, since it can worsen the situation by 
inflicting (micro-)lesions in the endometrium (Banerjee, 1966; Vande-
plassche and Bouters, 1982; Bolinder et al., 1988). It is not known 
whether placenta removal by light traction has the same negative 
effects. 
Systemic AB treatment of RFM in the absence of systemic illness has 
not proven to have any beneficial effects compared to a selective 
treatment (Drillich et al., 2006b), and should be discouraged. Never-
theless, the majority of veterinarians (64.4 %) initiate an AB treatment 
in a dairy cow with RFM and no fever. We suggest that a considerable 
proportion of this AB use (and associated treatment costs) can be avoi-
ded without deleterious effects on the animal’s wellbeing and perfor-
mance, by a better selection of the cows truly needing an AB therapy. It 
should be noted that this selection ideally includes other elements of the 
clinical examination besides the presence or absence of fever, as also 
suggested by the respondents in the comments section. 
As expected, the frequency of AB treatments increases when dairy 
cows with RFM also present fever. Remarkably, whereas 33.5 % of re-
spondents uniquely use the systemic route, almost two thirds of the 
respondents use the intrauterine administration route, alone or in 
combination with systemic AB. In literature, intrauterine AB treatment 
for cows with RFM and fever seems to have very little added value when 
Table 1 
Preference scores for the molecule choice in case of systemic antibiotic treat-
ment for retained fetal membranes in dairy cows 1: never used, 2: rarely used, 3: 
sometimes used, 4: often used, 5: always used. Results are expressed as the 
percentage of practitioners surveyed and as the number of answers/number of 
respondents. *Only the Flemish questionnaire made a further distinction be-
tween 1st and 3rd generation cephalosporins, while the Walloon questionnaire 
only covered cephalosporins, all classes combined.   
Dairy cows  




20.8 % 13.4 
% 






























20.0 % 14.8 
% 


























24.2 % 11.4 
% 











% 25.6 % 
14.1 
% 16.7 % 3.9 % 





19.7 % 8.5 % 23.9 % 0.0 % 
34/71 14/71 6/71 17/71 0/71 
Cephalosporins 3rd generation* 
70.4 
% 22.6 % 2.8 % 2.8 % 1.4 % 
50/71 16/71 2/71 2/71 1/71  
Table 2 
Preference scores for the molecule choice in case of systemic antibiotic treat-
ment for retained fetal membranes in beef cows 1: never used, 2: rarely used, 3: 
sometimes used, 4: often used, 5: always used. Results are expressed as the 
percentage of practitioners surveyed and as the number of answers/number of 
respondents. *Only the Flemish questionnaire made a further distinction be-
tween 1st and 3rd generation cephalosporins, while the Walloon questionnaire 
only covered cephalosporins, all classes combined.   
Beef cows  
1 2 3 4 5 
Tetracyclins 















3.4 % 3.4 % 
13.4 









55.0 % 22.1 % 10.1 
% 











70.5 % 12.8 % 
10.7 








Aminoglycosides alone or in 
combination 
43 % 20 % 17.5 
% 










65.4 % 17.9% 7.7 % 6.4% 2.6 % 
51/78 14/78 6/78 5/78 2/78 
Cephalosporins 1rst 
generation* 
77.5 % 15.5 % 2.8 % 4.2 % 0.0 % 
55/71 11/71 2/71 3/71 0/71 
Cephalosporins 3rd 
generation* 
78.9 % 12.7 % 2.8 % 4.2 % 1.4 % 
56/71 9/71 2/71 3/71 1/71  
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a systemic treatment is applied (Musah et al., 1987; Drillich et al., 2003; 
Kaitu’u et al., 2005; Goshen and Shpigel, 2006). 
Intrauterine treatment of RFM with water and antiseptic solutions (e. 
g. povidone-iodine) remains common practice, but is controversial. 
Although widely used in mares with RFM (Threlfall et al., 2007; Burden 
et al., 2019), there is no evidence of its efficacy in cows. As also 
demonstrated in another recent study (Hehenberger et al., 2015), tet-
racyclines are the most commonly used molecules for intrauterine AB 
treatment. This is logical, since chlortetracyclines are the only registered 
AB molecules on the market in Belgium for local treatment of RFM 
(Gustin, 2020). The use of tetracyclines is however controversial 
because they may interfere with the natural intrauterine inflammator-
y/immune system (Moller, 1967; Eiler and Fecteau, 2007; Gilbert, 
2018). 
The most frequently used AB molecules to systemically treat RFM 
were β-lactams (benzylpenicillin, amoxicillin and ampicillin), followed 
by tetracyclines and trimethoprim-sulfadiazine. Ample description of 
ceftiofur in clinical studies (Drillich et al., 2003, 2006a, 2006b; Haimerl 
et al., 2017) might have generalized the use of this molecule for the 
treatment of RFM, although current national recommendations strongly 
discourage its use and stimulate the use of alternatives (AMCRA, 2020a, 
AMCRA, 2020b). While the first generation cephalosporins were regu-
larly used by a quarter of the Flemish respondents, third generation 
cephalosporins were very rarely used. The majority of Walloon re-
spondents rarely or never use any cephalosporins. Altogether, the 
molecule choice by Belgian veterinarians seems to be in line with the 
AMCRA recommendations. The most commonly isolated bacterium in 
puerperal metritis is Escherichia coli (Ordell et al., 2016). The use of 
ampicillin seems justified because of its efficacy against Escherichia coli 
(Lehtolainen et al., 2003); accordingly, satisfactory clinical results have 
been observed when treating metritis with ampicillin (Lima et al., 2014). 
According to a recent Swiss survey, the most widely used molecule was 
tetracycline, followed by penicillin (Hehenberger et al., 2015). 
The same tendencies on RFM treatment were observed in beef cows. 
The majority of beef cows in Belgium are of the BB breed, which prac-
tically always calve via elective CS. A higher proportion of veterinarians 
seem to apply AB in beef cows with RFM, with or without fever, 
compared to dairy cows. We hypothesize that this may be explained 
because an AB injection has already been administered on the day of CS 
(Djebala et al., 2019), because veterinarians fear peritonitis when a cow 
develops RFM after CS, and because milk withdrawal times are not an 
issue in BB cows. The most frequently used molecules for systemic 
treatment are β-lactams, which are also the drug of choice for AB 
treatment during elective CS (Djebala et al., 2019). Remarkably, 7.4 % 
of respondents treating a beef cow with RFM and fever use the intra-
peritoneal route, which is popular also during elective CS (Djebala et al., 
2019). This seems to confirm the fear for peritonitis as a complication of 
RFM after CS. However, intraperitoneal use of AB is not registered in 
Belgium and its effectiveness and pharmacokinetics are unknown, and 
therefore this injection route seems hard to justify. 
Hormonal treatments were not frequently used by the practitioners 
participating in our study. This tendency is in accordance with the 
literature, where no convincing arguments could be found to promote 
hormonal treatment for RFM. Indeed, the use of oxytocin alone (Garcia 
et al., 1992; Palomares et al., 2010) or in combination with 
prostaglandins (Garcia et al., 1992) following calving did not decrease 
the incidence of RFM 24 h later. Also, there is no evidence that these 
hormonal treatments result in a faster expulsion of the retained mem-
branes (Frazer, 2005). 
Finally, the question remains whether or not we should treat cows 
with RFM and puerperal metritis at all. For obvious ethical reasons (not 
treating a sick cow with RFM and puerperal metritis), negative control 
studies are controversial and scarce. Only one study has included a 
negative control group that did not receive any treatment for RFM and 
clinical metritis (Goshen and Shpigel, 2006). This study did not prove 
the benefit of the use of intrauterine AB for RFM compared to no 
treatment. Pohl et al. (2016) have concluded that an initial 3 day 
ketoprofen treatment in the case of puerperal metritis could be helpful in 
reducing the total AB use in dairy cows since roughly 39 % of cows 
recovered clinically without ceftiofur, although 61 % of cows still 
required an AB treatment after ketoprofen. The latter study could be a 
cautious step towards a reduced AB use. 
5. Conclusion 
An opportunity exists to lower and rationalize AB use in the case of 
bovine RFM. According to current scientific literature, the use of AB in 
the treatment of RFM in cattle should be limited to cows with fever and, 
in these cases, a systemic treatment should be preferred. Many veteri-
narians apply AB in RFM cows not presenting clinical illness, which is 
discouraged in literature. Intrauterine AB administration is a common 
habit to treat RFM cows (with or without illness), which leads to higher 
AB use and their associated costs, although it has not been proven to be 
beneficial for the cows’ short-term health risks or reproductive perfor-
mance on the long term. Manual removal of the placenta is still a 
common practice among Belgian practitioners, although it has not 
proven to be effective and carries potential disadvantages. Concerning 
the molecule choice, practical routines are in line with national AB 
regulations. Beef cows with RFM are treated with AB more frequently 
than dairy cows, which can be explained by the more severe compli-
cation risks when RFM develops in an incised uterus. Changing treat-
ment routines will require raising awareness among veterinary students, 
practitioners and farmers on the subject of prudent antibiotic use and 
better communication of relevant clinical field trials. 
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Appendix A. 1: Sections 1–4 of the questionnaire 
Section 1: demographic information 
1. What is your sex?  
• Female  
• Male 
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2. Where did you finish your studies? If "elsewhere", please specify as a comment  
• Liège  
• Ghent  
• Elsewhere 
Make the comment of your choice here: 
3. How many years of practical experience do you have?  
• Less than 10  
• 11–20  
• 21–30  
• Above 30 
Section 2: case definition of RFM 
1. After how many hours do you consider a cow to suffer from retained fetal membranes?  
• > 6 h  
• > 12 h  
• > 24 h  
• > 36 h  
• > 48 h 
Section 3: therapeutic approach 
1. When you are consulted for a cow with retained fetal membranes, do you take her temperature? Please explain briefly  
• Never, because  
• Always, because  
• Sometimes, because 
Make the comment of your choice here: 
2. When you are consulted about a cow with retained fetal membranes, do you do a vaginal examination? Please explain briefly  
• Never, because  
• Always, because  
• Sometimes, because 
Make the comment of your choice here: 
3. When you are consulted for a cow with retained fetal membranes, do you try to manually remove the placenta?  
• Yes, I only apply traction without trying to detach the placenta from the endometrium  
• Yes, and if necessary I try to detach the placenta from the endometrium.  
• No 
4. At what temperature do you consider a cow with retained fetal membranes to have a fever?  
• Starting at 39 ◦C  
• Starting at 39.5 ◦C  
• Starting at 40 ◦C 
5. Is the presence or absence of fever a treatment criterion for you?  
• Yes  
• No 
6. Apart from fever, are there any other criteria that define your choice of treatment? (several answers possible)  
• No  
• Dehydration  
• Anorexia  
• Milk drop 
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• Abdominal straining  
• Another else 
Section 4: treatment options 
1. In a dairy cow with retained fetal membranes and no fever, which antibiotic therapy do you prefer? Clarify your answer  
• No antibiotic treatment  
• Antibiotics by uterine route only  
• Antibiotics by systemic route only  
• Uterine and general antibiotics 
Make the comment of your choice here: 
2. In a beef cow with retained fetal membranes and no fever, which antibiotic therapy do you prefer? Clarify your answer  
• No antibiotic treatment  
• Antibiotics by uterine route only  
• Antibiotics by systemic route only  
• Uterine and general antibiotics  
• Other (intraperitoneal, other combinations) 
Make the comment of your choice here: 
3. In a dairy cow with retained fetal membranes and fever, which antibiotic do you prefer? Clarify your answer  
• No antibiotic treatment  
• Antibiotics by uterine route only  
• Antibiotics by systemic route only  
• Uterine and general antibiotics 
Make the comment of your choice here: 
4. In a beef cow with retained fetal membranes and fever, which antibiotic do you prefer? Clarify your answer  
• No antibiotic treatment  
• Antibiotics by uterine route only  
• Antibiotics by systemic route only  
• Uterine and general antibiotics  
• Other (intraperitoneal, other combinations) 
Make the comment of your choice here: 
5. When treating a cow with intrauterine treatment for retained fetal membranes, which of the following products do you use? (1 = never, 2 = rarely, 3 =
sometimes, 4 = often, 5 = always)  
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6. When you give general antibiotic therapy to a dairy cow with retained fetal membranes, which of the following products do you use? (1 = never, 2 =
rarely, 3 = sometimes, 4 = often, 5 = always)  
7. When you give general antibiotic therapy to a beef cow with retained fetal membranes, which of the following products do you use? (1 = never, 2 =
rarely, 3 = sometimes, 4 = often, 5 = always)  
8. When you treat a dairy cow with retained fetal membranes with hormonal products, which of the following products do you use? (1 = never, 2 = rarely, 3 
= sometimes, 4 = often, 5 = always)  
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9. When you treat a beef cow with retained fetal membranes with hormonal products, which of the following products do you use? (1 = never, 2 = rarely, 3 
= sometimes, 4 = often, 5 = always)  
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